New drug ORB-021 enters early human testing for Hard-to-Treat cancers
NCT ID NCT06607939
First seen Feb 10, 2026 · Last updated Jun 20, 2026 · Updated 16 times
Summary
This early-stage trial is testing whether a new drug, ORB-021, is safe and tolerable for people with advanced solid tumors that have not responded to standard treatments. About 36 participants will receive the drug through an IV. The main goal is to find the best dose and check for side effects, not yet to prove it works against cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Honor Health Clinical Research
RECRUITINGScottsdale, Arizona, 85258, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
MDAC
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ORB-021
What this could lead to
If it works, this could point toward a new treatment option for people with advanced solid tumors who have run out of standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 36 people, focused on safety and dosing. It is too soon to know if ORB-021 will be effective or have manageable side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.